Attenuated human parainfluenza virus, methods and uses thereof
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsMario H. Skiadopoulos, Brian R. Murphy, Peter L. Collins, Sheila Nolan
Life of this patent
Estimating the term…
Abstract
The invention provides self replicating infectious recombinant paramyxoviruses. The recombinant paramyxovirus preferably have one or more attenuating mutations. In some embodiments, the recombinant paramyxovirus has a separate variant polynucleotide encoding a P protein and a separate monocistronic polynucleotide encoding a V protein. In some embodiments, recombinant paramyxovirus have at least one temperature sensitive mutation and one non-temperature sensitive mutation. Also provided are compositions and methods for using the recombinant paramyxoviruses as described herein.
Claims14
A recombinant, infectious, self-replicating human parainfluenza virus 2 (HPIV2) comprising a partial or complete polyhexameric genome or antigenome comprising a variant polynucleotide having:
- a monocistronic polynucleotide with an open reading frame (ORF) encoding a P protein, which does not encode a V protein, and
- a monocistronic polynucleotide with an open reading frame (ORF) encoding a V protein, wherein
- the two monocistronic polynucleotides are separated by a non-coding polynucleotide spacer sequence comprising a gene end transcription signal, intergenic transcription signal, and gene start transcription signal, wherein said P protein and said V protein are encoded by separate polynucleotides.
Dependencies are inferred from the claim text.